← Back to Search

Probing Treatment Right Eye for Meibomian Gland Dysfunction

N/A
Waitlist Available
Led By Sunali Goyal, MD
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
• Diagnosed Ocular Rosacea +/- Facial Rosacea
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Summary

Meibomian glands (MG) are modified sebaceous glands associated with the tarsus (collagenous structural component) of the upper and lower eyelids. Meibomian glands produce lipid-based secretions which are an integral and stabilizing part of the tear film. In blepharitis and ocular rosacea (two known causes of obstructive meibomian gland dysfunction (o-MGD), inflammation of the lid margins causes blockage of the meibomian gland orifices, changes in glandular secretions, and dropout of the glands themselves. This limits the production, secretion, and quality of meibum. With less oil in the tear film, the aqueous portion of tears is not stable and evaporates quickly which leads to dry eye.

Eligible Conditions
  • Meibomian Gland Dysfunction

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Improvements in participants symptoms as reflected in improvement in Ocular Surface Disease Index (OSDI) scores

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Probing Treatment Right EyeActive Control1 Intervention
Meibomian gland will be performed on the right upper eye lid of each participant.
Group II: Fellow Eye (Left) UntreatedPlacebo Group1 Intervention
The fellow eye (left) will be used at the untreated control

Find a Location

Who is running the clinical trial?

University of ArkansasLead Sponsor
494 Previous Clinical Trials
150,619 Total Patients Enrolled
Sunali Goyal, MDPrincipal InvestigatorUniversity of Arkansas
Joshua Hardin, MDPrincipal InvestigatorUniversity of Arkansas
~0 spots leftby Oct 2025